Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422734 · ClinicalTrials.gov registry record · Phase 3
Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 342
- Enrollment target
NCT00422734 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 342 participants.
The verdict
NCT00422734, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 342 participants
- Enrollment target
Study Summary
To determine if tadalafil 5 mg daily compared to placebo when given for 12 weeks improves getting and maintaining an erection in men with erectile dysfunction and if there are improvements in the sexual quality of life of the man and his female study partner
Interventions
- DRUG Placebo
- DRUG tadalafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00422734
The ClinicalTrials.gov registry entry for NCT00422734 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 342 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00422734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00422734 about?
NCT00422734 is a clinical study titled "Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life". To determine if tadalafil 5 mg daily compared to placebo when given for 12 weeks improves getting and maintaining an erection in men with erectile dysfunction and if there are improvements in the sexual quality of life of the man and his female study partner
What is the current status of trial NCT00422734?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 342 participants. The study started on 2006-11. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00422734?
The interventions under investigation include: Placebo (DRUG), tadalafil (DRUG).
Who is sponsoring clinical trial NCT00422734?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.